PASADENA, Texas – The San Jacinto College Center for Biotechnology has partnered with CellReady, a privately held cell therapy contract development and manufacturing organization, to launch an innovative, fast-track training curriculum for new hires in biomanufacturing. This four-week program is designed to significantly shorten onboarding time for manufacturing associates, providing them with concentrated and rigorous hands-on training to jumpstart their readiness to work in advanced cell therapy manufacturing.  Over the course of the program, trainees undergo 160 hours of both theoretical and practical, hands-on learning that cover the fundamentals of biomanufacturing through the operation of advanced workflows. The curriculum prepares new hires for the production of cell therapies, a cutting-edge cancer treatment, using the G-Rex cell production platform. The training, which took place at CellReady’s manufacturing site in Houston, was delivered by San Jacinto College Biotechnology faculty members, in collaboration with CellReady’s training team. “To our knowledge, this is the first collaboration of its kind between a community college and a cell therapy manufacturer to develop an intensive onboarding curriculum tailored specifically for cell therapy manufacturing technicians,” said Dr. Chris Wild, San Jacinto College assistant vice chancellor of biotechnology. “Together with CellReady, we’ve created a path to rapidly train professionals with advanced, hands-on techniques, using the G-Rex cell production platform, which is widely used in the industry today.”  This joint initiative provides clear benefits to all stakeholders. For San Jacinto College, it underscores the institution’s commitment to meeting industry needs with innovative, real-world training.  CellReady gains a streamlined, effective approach to onboarding that enables new technicians to make an immediate impact post-training. At the conclusion of the program, trainees are equipped with the skills and knowledge needed to manufacture cell therapies. Dr. Ignacio Nunez, CellReady’s chief operating officer, was impressed with the training provided and the speed that employees were able to grasp the critical components of the manufacturing process, stating “Thanks to the training program developed and delivered by San Jacinto College and CellReady, we were able to provide our new hires with the essential knowledge and skills to work in a GMP environment. In collaboration with San Jacinto College, we have debottlenecked operator qualification and made great strides toward our mission of bringing more of these life-saving therapies to patients one G-Rex at a time.” “This program not only equips new team members with qualifiable skills to contribute immediately upon completion of the training program, but it also sets a new standard for how training can be delivered in a highly regulated field,” said Dr. Nicole Bradley, program director for the Center for Biotechnology. The program’s success has inspired plans for additional training sessions to onboard future manufacturing professionals at CellReady, further strengthening the relationship between San Jacinto College and CellReady. The training curriculum for cell therapy developed in collaboration with this industry leader will be available as a program offering through the San Jacinto Center for Biotechnology. About CellReady CellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About San Jacinto College Surrounded by monuments of history, evolving industries, maritime enterprises of today, and the space age of tomorrow, San Jacinto College has served the people of East Harris County, Texas, since 1961. The College is one of the top 10 community colleges in the nation as designated by the Aspen Institute and was named an Achieving the Dream Leader College of Distinction in 2020. The College is a Hispanic-Serving Institution that spans five campuses, serving approximately 45,000 credit and non-credit students annually. It offers more than 200 degrees and certificates across eight major areas of study that put students on a path to transfer to four-year institutions or enter the workforce. The College is fiscally sound, holding bond ratings of AA+ by Standard & Poor’s and Aa2 by Moody’s.

[PRESS RELEASE] Paris (France), Houston (USA), San Francisco (USA) — November 25, 2024 — Lauxera Capital Partners announces the acquisition of Galen Data, a leading provider of secure, cloud-based connectivity solutions for medical devices. This transaction follows Lauxera’s 2022 acquisition of Matrix Requirements, a leading ALM and eQMS software solution for medical device R&D and Quality teams.  This strategic transaction brings together two industry leaders serving the same end-customers with highly complementary products. “The Galen team has built an exceptional product providing medical device companies a cost-effective, compliant, and secure solution for medical device cloud connectivity. Innovation in Medtech is no longer only about better electronic, metal, and plastic designs. Galen empowers Medtech companies to improve care by leveraging the data generated by their medical devices. “We are excited to work hand in hand with management to strengthen the company’s global commercial engine,” said Samuel Levy, Founding Partner, Lauxera Capital Partners.   For Galen Data, this acquisition represents an exciting new chapter with expanded financial resources and a broader, global team.   “We’re incredibly excited to join forces with Lauxera Capital Partners and Matrix Requirements. Their strategic insights and global reach will allow us to accelerate growth into new markets, expand our services, and continue delivering cutting-edge solutions to the medical device industry. This partnership empowers us to take our business to the next level and better serve our clients while pushing forward the innovation that’s at the core of everything we do,” Chris DuPont, CEO, Galen Data.  "This acquisition is an important step towards our vision to provide turnkey vertically-integrated software solutions to address pain points faced by medical devices companies. I am thrilled to welcome Galen’s team.” added Laurent Grandidier, Executive Chairman of the Board.  Lauxera Capital Partners was advised by Goodwin Proctor on legal and tax matters.  About Lauxera Capital Partners  Founded in January 2020, Lauxera Capital Partners is an independent asset management company based in France (Paris) and in the United States (San Francisco). Lauxera is a healthcare specialist investor working to promote the growth of European Healthtech companies. Its first fund, Lauxera Growth I, gathered 262m€ of capital from investors and had invested in 12 fast-growing Healthtech businesses in France, the UK, Germany, Sweden, Denmark and the United States. Led by a team of life sciences entrepreneurs and professional healthcare investors with more than 50 years’ experience, Lauxera aims to support the international commercial expansion of Europe's most promising Healthtech innovations. Lauxera’s highly focused investment approach, its intimacy with the US healthcare ecosystem, its distinctive understanding of innovation trends across Europe and the operating and investment experience of its partners enables Lauxera to be a strong value-add partner for its investee companies.  About Galen Data  Galen Data provides a secure, cloud-based platform designed to connect medical devices to the cloud, allowing for real-time data collection, storage, and analysis. Galen’s platform is compliant with key medical device industry standards, including FDA, HIPAA, GDPR, and CE Marking, which helps medical device companies accelerate time-to-market while ensuring regulatory compliance. Galen Data’s solution simplifies the process of managing connected medical devices by offering a secure and scalable infrastructure tailored to the needs of healthcare technology providers.  Galen Data is an ISO 13485:2016 certified company and is HITRUST r2 Certified on AWS.